Nanoviricides, Inc. (NYSE: NNVC) is a development-stage company that is creating special purpose nanomaterials for viral therapy. The company’s nanoviricide® class of drug candidates are designed to attack enveloped virus particles and to dismantle them. The company is developing drugs against a number of viral diseases, including H1N1 swine flu, H5N1 bird flu, seasonal influenza, HIV, oral and genital herpes, viral diseases of the eye (including EKC and herpes keratitis), hepatitis C, rabies, dengue fever, and Ebola virus, among others. For more information, visit the company’s website at www.nanoviricides.com